Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best large cap stocks to invest in for the long term. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was initiated with an Outperform rating by Scotiabank on November 12 with a $495 price target. The same day, Evercore ISI reiterated a Buy rating on the stock. However, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) received Hold ratings from Maxim Group analyst Naz Rehman on November 11 and Needham’s Joseph Stringer on November 10. Is V ...

Immuneering Corporation (IMRX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the s ...

Core Insights - Novavax, Inc. reported a 3Q25 GAAP EPS loss of –$1.25, which was $0.33 below estimates [1] - Revenue for the quarter was $70.45 million, exceeding expectations by $25.58 million, despite a year-over-year decline of 16.6% [1] Financial Performance - The GAAP EPS loss of –$1.25 indicates financial challenges for the company [1] - Revenue of $70.45 million represents a significant beat against expectations, highlighting some operational resilience despite the decline [1] Market Context - The decline in revenue year-over-year by 16.6% suggests ongoing difficulties in the market environment for Novavax [1]

Burning Rock Biotech (BNR), a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday. Despite strong technicals, BNR is a highly speculative and risky stock. Today’s Chart of the Day is not a buy recommendation. Investors should exercise caution, diversify, and use strict stop-loss strategies with BNR. Today’s Featured Stock Valued at $209 million, Burning Rock Biotech (BNR ...

Core Insights - Despite a turbulent year marked by geopolitical changes, technological advancements, and Federal Reserve policy shifts, investors are finding reasons to be optimistic as the SPDR S&P 500 ETF Trust (SPY) has gained approximately 12.7% year-to-date as of November 21, 2025 [1] Market Volatility - The early part of 2025 saw significant stock market volatility due to trade uncertainties under the Trump administration and a less dovish Federal Reserve [2] - April was particularly volatile, driven by President Trump's aggressive tariff measures, including the "Liberation Day" tariffs, which caused market shockwaves [4] Recovery Factors - Following the initial slump in April, easing trade tensions and subsequent trade negotiations helped stabilize the markets [5] - The Federal Reserve's first rate cut of the year in September lowered borrowing costs, which revived investor risk appetite, particularly benefiting the high-growth tech sector [5] AI Sector Challenges - The artificial intelligence sector faced overvaluation threats and concerns about circular financing in the latter half of the year, with notable figures like OpenAI's CEO suggesting the AI market may be in a bubble [6] ETF Performance - Several exchange-traded funds (ETFs) have emerged as strong performers in 2025: - Breakwave Tanker Shipping ETF (BWET) has shown a year-to-date performance increase of 134.4% [8] - Sprott Lithium Miners ETF (LITP) has increased by 72.6% year-to-date [9] - Simplify Health Care ETF (PINK) has gained 24.9% year-to-date [10] - Tema Oncology ETF (CANC) has risen by 41.9% year-to-date [11]

Core Viewpoint - FibroBiologics has successfully repaid all outstanding convertible promissory notes, strengthening its balance sheet and eliminating further dilution from conversions [1][2][3] Financial Developments - The company has paid off the convertible promissory notes issued to Yorkville, which were part of a Standby Equity Purchase Agreement (SEPA) allowing the sale of up to $25 million in common stock [1][2] - The first $15 million was advanced in three equal tranches, and with the repayment, there will be no further conversions into shares [2] - The SEPA remains active until December 20, 2026, permitting the company to sell an additional $10 million of its common stock under certain conditions [2] Strategic Focus - The repayment of convertible debt allows the company to concentrate on advancing its clinical programs, particularly the initiation of first-in-human trials [3] - The company is preparing to start a Phase 1/2 clinical trial for its fibroblast-based product candidate CYWC628 in diabetic foot ulcer patients in early 2026 [4] - Additionally, the company plans to submit Investigational New Drug applications for treatments targeting psoriasis and multiple sclerosis [4] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics for chronic diseases using fibroblast cells [8] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, and cancer [8]

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NYEvercore 8th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:00 a.m. E ...

Core Insights - ProPhase Labs, Inc. is hosting a webinar on December 1, 2025, featuring insights from Chairman and CEO Ted Karkus [1][2] - The company will discuss its healthcare assets, including the BE-Smart™ Esophageal Cancer Test, which targets a market valued between $7 billion and $14 billion [2] - ProPhase is also focusing on recovering over $50 million in COVID-19 receivables and expanding its consumer genomics business, Nebula Genomics [2] Company Overview - ProPhase Labs is a next-generation biotech and consumer products company dedicated to healthcare innovation and actionable insights [5] - The company is involved in Whole Genome Sequencing and developing diagnostics for early cancer detection [5] - ProPhase aims to create long-term value through executional excellence and a synergistic approach across its subsidiaries [5]

– Enlivex has adopted the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. – RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation. – Mr. Matteo Renzi, former Prime Minister of Italy has joined the Enlivex Board of Directors. – Enlivex to continue clinical development of Al ...

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21). Presentation details:Type: Company presentationDate: December 3, 2025Time: 2:30 – 2:55pm ETSpeakers: Ilan Hadar, Chief Executive Officer and Mirit Horenshtein-Hadar, Ch ...